Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

Insulin and glucagon exert opposing effects on glucose metabolism and, consequently,
pancreatic islet β-cells and α-cells are considered functional antagonists. The intra-islet …

abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …

Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are released from enteroendocrine cells in response to the …

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …

In the last two decades we have witnessed sizable progress in defining the role of
gastrointestinal signals in the control of glucose and energy homeostasis. Specifically, the …

The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha
cells and is an essential regulator of metabolic homeostasis. This review summarises …

Over the last few years, incretin‐based therapies have emerged as important agents in the
treatment of type 2 diabetes (T2D). These agents exert their effect via the incretin system …